Literature DB >> 28166808

Erratum to: A feasibility study of the clinical effectiveness and cost-effectiveness of individual cognitive behavioral therapy for panic disorder in a Japanese clinical setting: an uncontrolled pilot study.

Yoichi Seki1,2, Shinobu Nagata3, Takayuki Shibuya3, Naoki Yoshinaga3,4, Mizue Yokoo3, Hanae Ibuki3, Noriko Minamitani3, Muga Kusunoki5, Yasushi Inada5, Nobuko Kawasoe6, Soichiro Adachi6, Kensuke Yoshimura7, Michiko Nakazato3, Masaomi Iyo7, Akiko Nakagawa8, Eiji Shimizu8,3.   

Abstract

Entities:  

Year:  2017        PMID: 28166808      PMCID: PMC5294758          DOI: 10.1186/s13104-017-2398-y

Source DB:  PubMed          Journal:  BMC Res Notes        ISSN: 1756-0500


× No keyword cloud information.

Erratum to: BMC Res Notes (2016) 9:458 DOI 10.1186/s13104-016-2262-5

After publication of the original article [1], it came to the authors’ attention that there were typing errors in the data presented in Tables 2 and 4. The values in the EQ-5D index column for both tables were mistyped, and the correct versions (Tables 2 and 4) of both tables are published in this erratum.
Table 2

Outcome measures at each assessment point

PDSSPASPHQ-9GAD-7BFNEEQ-5D index
MeanSDMeanSDMeanSDMeanSDMeanSDMeanSD
Pre-CBT12.14.023.55.88.03.28.75.142.712.40.6650.2
Mid-CBT7.53.315.33.65.42.55.13.634.312.10.8070.2
Post-CBT5.53.511.65.75.23.14.53.331.712.60.8540.1
Pre-post CBTa −6.64.3***−11.96.6***−2.83.6**−4.23.6**−10.99.2 (ns)0.1890.20**
Effect size1.772.060.890.970.870.88

PDSS Panic Disorder Severity Scale, PAS Panic and Agoraphobia Scale, BFNE Brief Fear of Negative Evaluation Scale, PHQ-9 9-item patient health questionnaire, GAD-7 7-item generalized anxiety disorder scale

*** p < 0.001, ** p < 0.01

aMean changes from pre- to post-CBT time points

Table 4

EQ-5D dimensions at each assessment point

MobilitySelf-careUsual activitiesPain/discomfortAnxiety/depressionEQ-5D
MeanSDMeanSDMeanSDMeanSDMeanSDMeanSD
Pre-CBT1.20.61.10.31.70.61.90.71.90.70.6650.2
Mid-CBT1.30.51.00.01.30.51.50.51.30.50.8070.2
Post-CBT1.00.01.00.01.10.41.30.51.50.50.8540.1
Pre-post CBTa 0.20.10.6**0.6*0.5*0.189**
ES0.470.001.180.990.660.88

** p < 0.01, * p < 0.05

aSignificantly different between pre- and post-CBT periods

Outcome measures at each assessment point PDSS Panic Disorder Severity Scale, PAS Panic and Agoraphobia Scale, BFNE Brief Fear of Negative Evaluation Scale, PHQ-9 9-item patient health questionnaire, GAD-7 7-item generalized anxiety disorder scale *** p < 0.001, ** p < 0.01 aMean changes from pre- to post-CBT time points EQ-5D dimensions at each assessment point ** p < 0.01, * p < 0.05 aSignificantly different between pre- and post-CBT periods In addition, there were errors in the EQ‑5D and QALYs sub-section of the Results. In the second paragraph, the following sentence has been amended to change the post-CBT value from 0.199 to 0.189: “The mean changes in the EQ-5D index from baseline were 0.143 at mid-CBT and 0.189 at post-CBT.” In the same paragraph, the final sentence has been amended to correct the change in QALYs from 0.178 to 0.167: “Under the best conditions—namely, that EQ-5D maintained a high level at 12 months—the change in QALYs from baseline was estimated as 0.167 QALYs. Therefore, between 0.102 and 0.167 QALYs were gained per 1 year.” Finally, in the last paragraph of the sub-section, the JPY and US$ values have been corrected: “Using these values to convert the change in QALYs per 1 year into WTP values, we obtained values of JPY 510,000–835,000 (Japan) and US$ 6320–10,350 (United States). Because we provided patients 16 sessions of CBT, we estimated that patients would spend JPY 31,800–52,100 (Japan) and US$ 395–647 (US) per one session (50 min) of CBT.”
  1 in total

1.  A feasibility study of the clinical effectiveness and cost-effectiveness of individual cognitive behavioral therapy for panic disorder in a Japanese clinical setting: an uncontrolled pilot study.

Authors:  Yoichi Seki; Shinobu Nagata; Takayuki Shibuya; Naoki Yoshinaga; Mizue Yokoo; Hanae Ibuki; Noriko Minamitani; Muga Kusunoki; Yasushi Inada; Nobuko Kawasoe; Soichiro Adachi; Kensuke Yoshimura; Michiko Nakazato; Masaomi Iyo; Akiko Nakagawa; Eiji Shimizu
Journal:  BMC Res Notes       Date:  2016-10-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.